These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25239268)

  • 1. Oritavancin: first global approval.
    Markham A
    Drugs; 2014 Oct; 74(15):1823-8. PubMed ID: 25239268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oritavancin: A Novel Lipoglycopeptide.
    Mattox J; Belliveau P; Durand C
    Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
    Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oritavancin: a long-acting antibacterial lipoglycopeptide.
    Kaasch AJ; Seifert H
    Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oritavancin: a review in acute bacterial skin and skin structure infections.
    Syed YY; Scott LJ
    Drugs; 2015 Nov; 75(16):1891-902. PubMed ID: 26464319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial development in the era of emerging resistance.
    Sorlozano A; Carrasco C; Cabeza J; Villegas E; Gutierrez J
    Mini Rev Med Chem; 2009 Jul; 9(8):938-55. PubMed ID: 19601889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oritavancin for acute bacterial skin and skin structure infections.
    Messina JA; Fowler VG; Corey GR
    Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin: an investigational lipoglycopeptide antibiotic.
    Karaoui LR; El-Lababidi R; Chahine EB
    Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.
    Dunbar LM; Milata J; McClure T; Wasilewski MM;
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3476-84. PubMed ID: 21537018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
    Crandon J; Nicolau DP
    Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
    Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.